Dr Reddy’s Laboratories (RDY) has released an update. Dr Reddy’s Laboratories’ recent financial review by Ernst & Young ...

ALSO READ: Dr Reddy's clocks highest-ever revenue in Q2; net profit down 9.5% Meanwhile, Delhi-based Mankind Pharma reported ...

Indian equity benchmarks open higher, Sensex and Nifty show positive momentum, with key corporate news and technical analysis ...

Dr. Reddy's Labs reported a 15% decline in Q2 net profit, despite a 17% rise in revenue driven by global generics. While ...

Dr. Reddy's' US sales continued to struggle due to inventory adjustments and pricing pressures on key products, Citi said.

The brokerage expects the new business avenues to take a few years before they start contributing profitably to the ...

Dr Reddy’s Laboratories posted a mixed performance in Q2FY25, reporting record revenue of Rs 8,038.2 crore, marking a strong ...

Shares of Dr. Reddy's Laboratories Ltd. will be closely watched in Wednesday's trading as its revenue for the September ...

Dr Reddy's revenue surged by 17 percent to an all-time high of ... Despite this, it reported a 15 percent on year drop in its ...

New Delhi: Pharma major Dr Reddy’s Laboratories (DRL ... Its total operating expenses grew 34.3 per cent to Rs3,021.8 crore ...

Chennai: Pharma market reported better revenue growth in Q2 FY25 against the year-ago quarter, mainly driven by price rise ...